Tag Archive for: Altimmune

Patients treated with Altimmune’s investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of those taking the highest dose lost at least 20% of their body weight.

The drugmaker, which will begin a mid-stage trial for the drug in mid-2023, is entering the race to develop an obesity treatment, which has contenders including Altimmune, Novo Nordisk, and Eli Lilly.

Altimmune released mid-stage data Tuesday showing pemvidutide helped reduce patients’ weight by 10%, but the company’s shares tumbled 55% over safety concerns with the obesity drug.